PMID- 15187202
OWN - NLM
STAT- MEDLINE
DCOM- 20041006
LR  - 20151119
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 38
IP  - 7-8
DP  - 2004 Jul-Aug
TI  - Omalizumab: a novel therapy for allergic asthma.
PG  - 1236-42
AB  - OBJECTIVE: To review the pharmacology, efficacy, and safety of omalizumab, 
      focusing on the treatment of allergic asthma. DATA SOURCES: A MEDLINE search 
      (1966-November 2003) was conducted using the key words omalizumab, Xolair, and 
      Rhu-MAB25, with studies limited to those in humans and published in English. 
      References of identified articles were reviewed for additional citations. STUDY 
      SELECTION AND DATA EXTRACTION: Clinical trials evaluating the pharmacology, 
      efficacy, and safety of omalizumab for treatment of allergic asthma in patients 
      aged >or=12 years were selected. Clinical trials examining utility in pediatric 
      patients were also reviewed. DATA SYNTHESIS: Omalizumab's ability to form 
      complexes with unbound immunoglobulin E (IgE) translates into decreased unbound 
      serum IgE levels and high-affinity IgE receptors on basophils, as well as 
      attenuation of early and late allergic response in patients with allergic asthma. 
      Results of clinical trials demonstrated that omalizumab administered 
      subcutaneously is a safe and effective treatment for moderate to severe allergic 
      asthma. Generally, omalizumab has a mild adverse effect profile. Omalizumab may 
      be particularly useful for treatment of moderate to severe allergic asthma in 
      patients who are poorly controlled on conventional therapy, experience adverse 
      effects secondary to high-dose or prolonged corticosteroid treatment, or who have 
      frequent exacerbations because of poor medication adherence. The high cost 
      associated with omalizumab treatment may be prohibitive for some patients, 
      thereby limiting its utility. CONCLUSIONS: Omalizumab is a safe and effective 
      therapy for treatment of moderate to severe allergic asthma in 
      difficult-to-treat, high-risk patients.
FAU - Davis, Lorrie A
AU  - Davis LA
AD  - Department of Pharmacy, University of Virginia Health System, PO Box 800674, 
      Charlottesville, VA 22908-0674, USA. ld4z@virginia.edu
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20040608
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Anti-Allergic Agents/economics/pharmacology/*therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/economics/pharmacology/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*drug therapy
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Omalizumab
MH  - Quality of Life
RF  - 23
EDAT- 2004/06/10 05:00
MHDA- 2004/10/07 09:00
CRDT- 2004/06/10 05:00
PHST- 2004/06/10 05:00 [pubmed]
PHST- 2004/10/07 09:00 [medline]
PHST- 2004/06/10 05:00 [entrez]
AID - aph.1D626 [pii]
AID - 10.1345/aph.1D626 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2004 Jul-Aug;38(7-8):1236-42. doi: 10.1345/aph.1D626. Epub 2004 
      Jun 8.